High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Siesing, Christina; Sorbye, Halfdan; Dragomir, Anca; Pfeiffer, Per; Qvortrup, Camilla; Pontén, Fredrik; Jirström, Karin; Glimelius, Bengt; Eberhard, Jakob

Published in:
PLOS ONE

DOI:
10.1371/journal.pone.0182512

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY

Citation for published version (APA):
Siesing, C., Sorbye, H., Dragomir, A., Pfeiffer, P., Qvortrup, C., Pontén, F., ... Eberhard, J. (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE, 12(8), [e0182512]. https://doi.org/10.1371/journal.pone.0182512

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 28. Apr. 2019
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Christina Siesing1*, Halfdan Sorbye2, Anca Dragomir3, Per Pfeiffer4, Camilla Qvortrup4, Fredrik Pontén3, Karin Jirström1, Bengt Glimelius5, Jakob Eberhard1

1 Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Skåne University Hospital, Lund, Sweden, 2 Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway, 3 Section of Pathology, Uppsala University Hospital and Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 4 Department of Oncology, Odense University Hospital, Odense, Denmark, 5 Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden

* christina.siesing@med.lu.se

Abstract

Background

High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy.

Methods

Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS).

Results

High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively).

Conclusion

High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.
Introduction

Colorectal cancer (CRC) is the third most common cancer in the world affecting 1.4 million people each year [1]. Approximately 20% have metastatic CRC (mCRC) at the time of diagnosis and about 20% subsequently develop metastatic disease, most with incurable disease [2]. Median survival for mCRC varies between 5–6 months in untreated patients and approaches 30 months in selected groups with good performance status having received optimal treatment [3–6]. Palliative chemotherapy aims to prolong the life of patients and ameliorate quality of life. There is a great need to identify biomarkers that predict response to chemotherapy, in order to save patients from affliction and contribute to better palliation. Chemotherapy for mCRC is based on 5-fluorouracil (5-FU) with the addition of either irinotecan or oxaliplatin. Irinotecan combined with 5-FU, as in FOLFIRI, increases progression-free survival (PFS) and overall survival (OS) [7]. Oxaliplatin combined with 5-FU, as in FOLFOX, increases PFS and likely also OS [7, 8]. Oxaliplatin cross-links the DNA strands and induces apoptosis [9]. Oxaliplatin works synergistically with 5-FU, probably via down regulation of thymidylate synthase [10]. First-line chemotherapy with irinotecan based chemotherapy or oxaliplatin based chemotherapy seem to give a similar overall survival and no data have shown preference for one schedule over the other as first-line treatment [11].

RBM3 and metastatic colorectal cancer

RNA-binding motif protein 3 (RBM3) is an RNA and DNA-binding protein that in response to various types of cellular stress, e.g. hypothermia [12], hypoxia [13], and oxidative stress [14], is required for cell proliferation [12, 15]. Silencing RBM3 decreases the sensitivity to cisplatin in ovarian cancer cell lines [16]. High RBM3 expression has been associated with improved survival in a number of malignancies, e.g. breast cancer, malignant melanoma, uroepithelial cancer, ovarian cancer, colorectal cancer, gastroesophageal cancer, and testicular cancer [16–22].

In CRC, the beneficial prognostic value of high RBM3 expression has been demonstrated in three independent studies [19, 23, 24], mainly including patients with stage II-III disease. To our best knowledge, the relationship between RBM3 expression and response to chemotherapy in mCRC has not yet been reported. Therefore, this study aimed to evaluate RBM3 as a prognostic factor in mCRC, overall and in relation to the choice of first-line chemotherapy.

Materials and methods

Patients

Sorbye et al have previously described the cohort [4, 25] which consists of 798 patients with unresectable mCRC diagnosed in the catchment area of the oncology units at three university hospitals; Odense University Hospital in Denmark, Haukeland University Hospital in Norway and Uppsala University Hospital in Sweden. All patients diagnosed with mCRC between August 2003 and October 2006 were prospectively registered at referral or using regional cancer registers. Written informed consent was obtained from all participants seen at the clinics. The intention of the cohort was to prospectively study different outcomes in an unselected population with mCRC.

Tumour tissue microarrays (TMAs) from mainly the primary tumour (5 cases from metastatic tissue) were constructed from 462 (58%) cases and RBM3 expression could be evaluated in 455 (98%) of these. In the remaining cases, the material was not sufficient to take a core for TMA, containing too much necrotic tissue to evaluate or not available [25]. A flowchart is shown as S1 Fig. The study was approved by the ethical committees in Norway (Regional Committee for medical and health research ethics-REC West 2009/2052), Sweden.
Ethical Committee Uppsala 2015/419) and Denmark (The Regional Scientific Ethical Committees for Southern Denmark S-20162000-48).

Tissue microarray construction
TMAs were generated for protein expression profiling using immunohistochemistry (IHC). IHC staining, slide scanning and evaluation of outcome were performed in accordance with strategies and standards used in the Human Protein Atlas [26, 27]. Original diagnostic tumour blocks were used as donor blocks for the recipient TMA blocks. Representative tumour tissue from each tumour was sampled in duplicate cores of 1 mm in diameter and assembled in the TMAs. A corresponding haematoxylin and eosin stained section was produced from each TMA block to control for quality and presence of tumour cells.

Antibodies
IHC was performed as previously described [27], in brief, 4 μm sections of the TMA blocks were cut and automated IHC was performed using a Lab Vision Autostainer 480 (Thermo Fisher Scientific). The mouse monoclonal anti-RBM3 antibody (CAB062559 / clone 0296, Atlas Antibodies AB, Stockholm, Sweden, diluted 1:1 000) was used as primary antibody.

Analysis of immunohistochemical staining
The IHC staining was evaluated by CS and KJ, who were blinded to clinical and outcome data. Interobserver differences were discussed in order to reach consensus. RBM3 expression was evaluated both in the cytoplasm and in the nuclei, whereby the fraction of positive cells was estimated, and the staining intensity denoted as 0 (negative), 1 (mild), 2 (moderate) and 3 (strong). A multiplier of fraction and intensity was constructed regarding nuclear and cytoplasmic expression (nuclear and cytoplasmic score), concluding a score between 0–3.

Statistical analyses
Chi square test was used to examine the associations between the nuclear and cytoplasmic RBM3 score and clinicopathological characteristics. Kaplan-Meier and log rank test were applied to illustrate differences in OS and PFS according to RBM3 expression. Classification and regression tree (CRT) analysis was applied to estimate the ultimate prognostic cut-off for the nuclear and cytoplasmic RBM3 scores, respectively. A classification based on negative and positive RBM3 expression was also used. Cox regression proportional hazards models were used to access the impact of RBM3 expression on OS and PFS in both univariable and multivariable analyses. PFS was calculated as time from start of first-line treatment until progression or death. A P-value <0.05 was considered statistically significant. All statistical analyses were preformed using IBM SPSS Statistics version 23.

Results
RBM3 expression in relation to patient and tumour characteristics
Among the 455 evaluable cases, 46 (10%) cases were negative for nuclear RBM3 expression and 67 (15%) cases were negative for cytoplasmic RBM3 expression. In the remaining cases, RBM3 was expressed in various intensities and fractions in the nuclei and/or cytoplasm. CRT analysis determined an optimal prognostic cut off at 0.550 for nuclear RBM3 expression and at 0.025 for cytoplasmic RBM3 expression. 166 (36%) cases were denoted as having low and 289 (64%) as having high nuclear expression, and 126 (28%) cases were denoted as having low and 329 (72%) cases as having high cytoplasmic expression, retrospectively. Sample IHC images
are shown in Fig 1. Associations of nuclear RBM3 expression with clinicopathological characteristics are shown in Table 1, and for cytoplasmic expression in S1 Table. High nuclear RBM3 expression was statistically significant associated with BRAF wild type tumours, and RBM3 expression was significantly higher in patients who underwent secondary surgery and received irinotecan based treatment. High cytoplasmic RBM3 expression was significantly associated with age <75 years, BRAF wild type tumour, secondary surgery and irinotecan based treatment. Positive nuclear RBM3 expression was significantly more frequent in tumours located in the rectum, in BRAF wildtype tumours and in metachronous disease. Positive cytoplasmic RBM3 expression was significantly more frequent in BRAF wildtype tumors, in patients who had undergone secondary surgery and with metachronous disease.

RBM3 expression in relation to overall survival

Kaplan-Meier analyses demonstrated that high RBM3 expression was associated with a significantly longer OS in the entire cohort, both for nuclear (Fig 2A, p<0.001) and cytoplasmic (Fig 2B, p<0.001) expression. This difference remained statistically significant also after exclusion of cases that had received adjuvant treatment (n = 59, data not shown). Median survival was 13 months in the group with high nuclear RBM3 expression and 7 months in the group with low RBM3 expression (p = 0.001). In the group with high cytoplasmic RBM3 expression the median survival was 13 months and 7 months in the group with low cytoplasmic RBM3 expression (p = 0.005). Dichotomisation of RBM3 expression comparing positive to negative expression, revealed a significantly longer OS regarding cytoplasmic expression, but not regarding nuclei expression (S2 Fig).

As shown in Table 2, these associations were confirmed in univariable Cox regression analyses (HR = 0.61, 95% CI = 0.50–0.74 for nuclear and HR = 0.61, 95% CI = 0.49–0.76 for cytoplasmic expression), and remained statistically significant in multivariable analyses.
Table 1. Associations between nuclear RBM3 expression and clinicopathological characteristics. ALP; alkaline phosphatase, CEA; carcinoembryonic antigen, KRAS; Kirsten rat sarcoma. (Regarding cytoplasmic expression see S1 Table).

|                        | High Expression | Low expression | \( p \)-value | Positive | Negative | \( p \)-value |
|------------------------|-----------------|----------------|---------------|----------|----------|---------------|
|                        | N (%)           | N (%)          |               | N (%)    | N (%)    |               |
| **Age**                |                 |                |               |          |          |               |
| <75 years              | 198 (69)        | 102 (61)       | 0.126         | 271 (66) | 29 (63)  | 0.663         |
| \( \geq 75 \) years   | 91 (31)         | 64 (39)        |               | 138 (34) | 17 (37)  |               |
| **Sex**                |                 |                |               |          |          |               |
| Female                 | 141 (49)        | 89 (54)        | 0.322         | 202 (49) | 28 (61)  | 0.140         |
| Male                   | 148 (51)        | 77 (46)        |               | 207 (51) | 18 (39)  |               |
| **Performance status** |                 |                |               |          |          |               |
| 0–1                    | 199 (69)        | 105 (63)       | 0.222         | 274 (67) | 30 (65)  | 0.809         |
| >1                     | 90 (31)         | 61 (37)        |               | 135 (33) | 16 (35)  |               |
| **Primary site**       |                 |                |               |          |          |               |
| Colon                  | 213 (75)        | 127 (78)       | 0.352         | 300 (74) | 40 (89)  | 0.032         |
| Rectum                 | 73 (25)         | 35 (22)        |               | 103 (26) | 5 (11)   |               |
| Missing                | 4               | 3              |               | 6        | 1        |               |
| **ALP µg/l**           |                 |                |               |          |          |               |
| Normal                 | 115 (46)        | 62 (42)        | 0.503         | 158 (44) | 19 (50)  | 0.463         |
| Elevated               | 137 (54)        | 85 (58)        |               | 203 (56) | 19 (50)  |               |
| Missing                | 19              | 37             |               | 48       | 8        |               |
| **BRAF**               |                 |                |               |          |          |               |
| Wild-type              | 234 (83)        | 117 (72)       | 0.010         | 324 (81) | 27 (63)  | 0.005         |
| Mutated                | 48 (17)         | 44 (27)        |               | 76 (19)  | 16 (37)  |               |
| Missing                | 7               | 5              |               | 9        | 3        |               |
| **KRAS**               |                 |                |               |          |          |               |
| Wild-type              | 160 (57)        | 99 (63)        | 0.243         | 232 (58) | 27 (66%) | 0.349         |
| Mutated                | 121 (43)        | 59 (37)        |               | 166 (42) | 12 (34)  |               |
| Missing                | 8               | 8              |               | 11       | 7        |               |
| **CEA µg/l**           |                 |                |               |          |          |               |
| Normal \( \leq 5 \)   | 46 (28)         | 22 (25)        | 0.585         | 61 (27)  | 7 (33)   | 0.502         |
| Elevated \( >5 \)     | 117 (72)        | 66 (75)        |               | 169 (74) | 14 (67)  |               |
| Missing                | 126             | 78             |               | 179      | 25       |               |
| **Time for metastasation** |            |                |               |          |          |               |
| Synchronous            | 142 (49)        | 96 (58)        | 0.074         | 207 (51) | 31 (67)  | 0.031         |
| Metachronus            | 147 (51)        | 70 (42)        |               | 202 (49) | 15 (33)  |               |
| **Secondary curative surgery** | |                |               |          |          |               |
| Yes                    | 33 (11)         | 2 (1)          | \(<0.001\)    | 34 (8)   | 1 (2)    | 0.138         |
| No                     | 256 (89)        | 163 (99)       |               | 374 (92) | 45 (98)  |               |
| Missing                | 1               |                |               | 1        |          |               |
| **First line chemotherapy** |            |                |               |          |          |               |
| Oxaliplatin-based      | 113 (39)        | 53 (32)        | 0.015         | 151 (37) | 15 (32)  | 0.132         |
| Irinotecan-based       | 43 (15)         | 17 (10)        |               | 57 (14)  | 3 (7)    |               |
| 5-FU single            | 27 (9)          | 30 (18)        |               | 47 (11)  | 10 (22)  |               |
| Best Supportive care   | 88 (31)         | 56 (34)        |               | 129 (32) | 15 (32)  |               |
| Other                  | 17 (6)          | 10 (6)         |               | 25 (6)   | 3 (7)    |               |

\[ \text{HR} = 0.67, \ 95\% \ CI = 0.50–0.90 \text{ for nuclear and } \text{HR} = 0.66, \ 95\% \ CI = 0.48–0.91 \text{ for cytoplasmic expression}. \text{ When nuclear and cytoplasmic expressions were used as continuous variables} \]
statistically significant associations, with a prolonged OS, were seen. The associations only remained statistically significant for nuclear RBM3 expression in a multivariable analysis (Table 2).

### Prognostic value of RBM3 expression in relation to chemotherapy

Several associations were seen between RBM3 expression and PFS in strata according to high and low RBM3 expression and type of treatment given as first-line. PFS was longer for patients with tumours displaying high nuclear or cytoplasmic RBM3 expression who received oxaliplatin based treatment as first-line chemotherapy, in comparison to irinotecan based treatment (p-value 0.020 for nuclear expression and 0.022 for cytoplasmic expression). (Fig 3A and 3B)

The median PFS was 9.35 months in the group with high nuclear RBM3 expression that received oxaliplatin based chemotherapy and 8.80 months in the group with high nuclear expression that received irinotecan based chemotherapy (p = 0.002). In the group with high cytoplasmic expression the median PFS was 8.99 months in the oxaliplatin group and 8.77 in the irinotecan group (p = 0.028).

Kaplan-Meier analysis of OS revealed that patients with tumours displaying high nuclear or cytoplasmic RBM3 expression who received oxaliplatin based treatment as first-line chemotherapy had significantly longer survival compared to all other strata (Fig 3C and 3D). Especially long-term survival was increased if oxaliplatin based chemotherapy was used as first-line treatment when RBM3 expression was high. This difference remained statistically significant also after exclusion of patients who had received adjuvant treatment (n = 59, data not shown). As seen in S2 Fig, positive RBM3 expression and oxaliplatin based treatment as first-line meant a significantly longer PFS (p = 0.022 for nuclear and p = 0.030 for cytoplasmic expression) compared to irinotecan based treatment.

As shown in Table 3 and S3 Table high nuclear and cytoplasmic expression was associated with complete or partial response to first-line chemotherapy, prolonged median PFS and initiation of second line chemotherapy. Prolonged PFS was the only statistically significant difference between the groups of positive and negative RBM3 expression and was seen regarding cytoplasmic expression.

There was a statistically significant interaction between RBM3 expression and oxaliplatin based treatment, in relation to PFS (p = 0.047). No such interaction was seen in relation to OS (data not shown).

Notably, there were no significant differences in PFS or OS between patients having received oxaliplatin based treatment and those who had received other types of chemotherapy regardless
of RBM3 expression (S3 Fig). Synchronous disease was associated with oxaliplatin based treatment, however no other statistically significant differences regarding patient characteristics between the oxaliplatin treated group and the irinotecan treated group were seen (S2 Table).

**Discussion**

Our results demonstrate that high RBM3 expression correlates with longer OS in patients with mCRC. In patients with tumours displaying high RBM3 expression, we have also shown a
significantly longer PFS in those treated with first-line oxaliplatin based chemotherapy compared to those treated with first-line irinotecan based chemotherapy, although the actual survival gain was less then one month. The association of high RBM3 expression with OS has previously not been studied in a cohort with only mCRC patients. Melling et al [23] evaluated RBM3 expression in primary CRC (stages I-III), and found an association between high RBM3 expression in primary CRC (stages I-III), and found an association between high

Table 3. Treatment and treatment response. Divided according to high and low nuclear RBM3 expression, and positive and negative nuclear RBM3 expression. (Regarding cytoplasmic expression see S3 Table).

| Nuclear expression RBM3 | All patients | High expression | Low expression | p-value | Positive | Negative | p-value |
|-------------------------|-------------|-----------------|---------------|---------|----------|----------|---------|
|                         | N(%)        | N (%)           | N (%)         |         | N (%)    | N (%)    |         |
| All patients            | 455         | 289 (64)        | 166 (36)      | 0.292   | 255 (62) | 28 (61)  | 0.845   |
| 1-line chemotherapy     | 283 (62)    | 175 (61)        | 108 (65)      | 0.143   | 151 (30) | 15 (32)  | 0.542   |
| 1-line combination oxaliplatin | 166 (36) | 113 (39)        | 53 (71)       | 0.094   | 54 (13)  | 3 (7)    | 0.190   |
| 1-line combination irinotecan | 57 (13)   | 42 (15)         | 15 (9)        |         |          |          |         |
| Response rate 1-line    |             |                 |               |         |          |          |         |
| CR/PR                   | 103 (23)    | 76 (26)         | 27 (16)       | 0.015   | 94 (23)  | 9 (20)   | 0.114   |
| PD                      | 45 (10)     | 24 (8)          | 21 (13)       |         | 37 (9)   | 8 (17)   |         |
| PFS 1-line median in months | 7.85      | 8.93            | 6.08          | <0.001  | 7.95     | 6.60     | 0.319   |
| 2-line chemotherapy     | 163 (36)    | 118 (41)        | 45 (33)       | 0.004   | 148 (36) | 15 (33)  | 0.624   |
| Response rate 2-line    |             |                 |               |         |          |          |         |
| CR/PR                   | 25 (5)      | 20 (7)          | 5 (3)         | 0.208   | 24 (6)   | 1 (2)    | 0.176   |
| PD                      | 56 (12)     | 37 (13)         | 19 (11)       |         | 48 (12)  | 8 (17)   |         |

CR = complete response, PR = partial response, PD = progressive disease as best response, PFS = progression free survival

https://doi.org/10.1371/journal.pone.0182512.t003
RBM3 expression and longer OS. Hjelm et al [19] studied two different cohorts and only 15% of the patient had stage IV disease. They did however not see any correlation between RBM3 expression and disease stage. Of note, while previous studies in primary CRC found nuclear RBM3 expression to be the strongest prognostic factor [19, 23], the results from the present study demonstrate that not only nuclear, but also cytoplasmic RBM3 expression was significantly associated with prolonged survival. These associations between high RBM3 expression and prolonged oxaliplatin response are in line with previous findings in epithelial ovarian cancer, where a high RBM3 expression was associated with an improved prognosis, and silencing of RBM3 in ovarian cancer cells led to a decreased sensitivity to cisplatin [16].

The optimal prognostic and/or predictive cutoff for RBM3 remains to be established, preferably in prospective studies. Varying cutoffs have been used in previous studies, i.e. week versus strong in the paper by Melling and al[23] and negative versus positive in the paper by Hjelm et al[19]. Our analyses are based on both CRT analyses, and positive versus negative expression, with similar prognostic value, although the former was more significant. The CRT based cutoff appears to well in line with the cutoff used in the study by Melling et al[23].

High nuclear and high cytoplasmic RBM3 expression were associated with BRAF wild type, secondary surgery and irinotecan based treatment. Positive expression, in comparison to negative expression, was related to rectal tumours and BRAF wild type regarding nuclear expression and BRAF wild type and secondary surgery regarding cytoplasmic expression. The association of high RBM3 expression with BRAF wild type tumours is in accordance with earlier reports. Yokota et al [28] among others, have shown that BRAF mutation is associated with shorter OS, which has also been shown in this cohort [25]. Of note, the frequency of BRAF mutation in this cohort is higher compared to prior reports probably due to the non-selected cohort, whereas other reported rates of BRAF mutation often refer to groups that have been included in a clinical trial [25]. The finding of RBM3 expression being significantly higher in cases that had undergone secondary surgery further underpins its association with a less aggressive tumour phenotype, since secondary surgery is relevant when the metastatic burden is limited and the metastases are resectable upfront or after conversion chemotherapy.

All tumours in the herein examined cohort are derived from patients with unresectable mCRC, a group of patients who often have a limited survival. Nevertheless, even in this patient category, high RBM3 expression was demonstrated to be an independent factor of a prolonged survival. It must however be pointed out that the tumour samples examined in this study were mainly obtained from the primary tumours. Moreover, there were no paired specimens from primary tumours and metastases. Therefore, we cannot draw any conclusions on the expression of RBM3 in the metastases, which may differ from the primary tumours. However, since chemotherapy may alter the expression of biomarkers [29, 30], the survival analyses were also performed after exclusion of patients who had received adjuvant chemotherapy, with similar results. A few other studies have compared RBM3 expression in primary tumours and metastases. In malignant melanoma, Jonsson et al [17] reported that RBM3 expression was downregulated in metastases as compared with primary tumours. In contrast, in oesophageal and gastric adenocarcinoma, RBM3 expression was similar in primary tumours and lymph node metastases [22].

Considering this, the number of TMAs available (58%) must be considered adequate. It could be discussed if TMA cores are representative of the whole tumour. To adjust for heterogeneity issues, duplicate 1 mm cores were obtained from different tumour areas. Furthermore, the TMA technique is a good method to demonstrate the connection between molecular alterations and clinical endpoints [31].

It is important to bear in mind that different physicians selected treatment for their patients and we can only speculate on the rationale for selecting a certain treatment. Irinotecan based
treatment were, for example, initiated more often to patients that had metachronous disease. However, the difference in OS, regarding both nuclear and cytoplasmic expression, remained significant when adjuvant treated patients were excluded.

Palliative chemotherapy is a balance act between effects and side effects. Peripheral neuropathy is a common side effect of oxaliplatin treatment that may lead to considerable disability in everyday life, for example leading to difficulties using a keyboard or buttoning a shirt. Since the effect of oxaliplatin appears to be limited in patients with tumours displaying low RBM3 expression, several patients could be spared suffering, at least temporarily, if another agent is given in first-line.

In summary, the results demonstrate that high RBM3 expression is associated with prolonged survival in patients with mCRC, in particular in those having received first-line oxaliplatin based chemotherapy. These findings merit further study, since they are of potential clinical relevance. It would also be of interest to explore the impact of RBM3 expression on oxaliplatin sensitivity in CRC cells in vitro.

Supporting information

S1 Table. Associations between cytoplasmic RBM3 expression and clinicopathological characteristics. ALP; alkaline phosphatase, CEA; carcinoembryonic antigen, KRAS; Kirsten rat sarcoma.
(XLSX)

S2 Table. Patient characteristics regarding type of chemotherapy given as first-line. CEA; carcinoembryonic antigen.
(XLSX)

S3 Table. Treatment and treatment response divided according to high and low cytoplasmic RBM3 expression and positive and negative cytoplasmic RBM3 expression. CR = complete response, PR = partial response, PD = progressive disease.
(XLSX)

S1 Fig. A flowchart outlining cases available for tissue microarray construction and analysis of RBM3 expression within the entire cohort of 798 cases.
(TIF)

S2 Fig. Kaplan-Meier estimates of overall survival according to (A) nuclear and (B) cytoplasmic RBM3 expression.
(TIF)

S3 Fig. Kaplan-Meier estimates of (A) progression free survival and (B) overall survival according to chemotherapy regimen given as first-line.
(TIF)

Acknowledgments

This study was supported by grants from the Swedish Research Council, KJ, JE, the Swedish and Norwegian Cancer Society, BG, HS, the Swedish Government Grant for Clinical Research, KJ, the Kamprad Family Foundation, JE, Knut and Alice Wallenberg Foundation, FP, the Gunnar Nilsson Cancer Foundation, KJ, Lund University Faculty of Medicine, KJ, and the Lund University Hospital Research Grants KJ.
Author Contributions

Conceptualization: Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard.

Formal analysis: Christina Siesing, Karin Jirström, Jakob Eberhard.

Funding acquisition: Jakob Eberhard.

Investigation: Christina Siesing, Karin Jirström, Bengt Glimelius, Jakob Eberhard.

Project administration: Christina Siesing.

Resources: Jakob Eberhard.

Supervision: Karin Jirström, Jakob Eberhard.

Validation: Karin Jirström, Jakob Eberhard.

Visualization: Christina Siesing, Karin Jirström.

Writing – original draft: Christina Siesing.

Writing – review & editing: Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87–108. Epub 2015/02/06. https://doi.org/10.3322/caac.21262 PMID: 25651787.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015; 65(1):5–29. Epub 2015/01/07. https://doi.org/10.3322/caac.21254 PMID: 25559415.

3. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2005; 5(4):292–4. Epub 2005/12/17. PMID: 16356309.

4. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009; 115(20):4679–87. Epub 2009/06/30. https://doi.org/10.1002/cncr.24527 PMID: 19562777.

5. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2014; 15(10):1065–75. Epub 2014/08/05. https://doi.org/10.1016/S1470-2045(14)70330-4 PMID: 25088940.

6. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology. 2015; 16(13):1306–15. Epub 2015/09/05. https://doi.org/10.1016/S1470-2045(15)00122-9 PMID: 26338525.

7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet. 2000; 355(9209):1041–7. http://dx.doi.org/10.1016/S0140-6736(00)02034-1.

8. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2000; 18(16):2938–47. Epub 2000/08/16. https://doi.org/10.1200/JCO.2000.18.16.2938 PMID: 10944126.

9. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Seminars in oncology. 1998; 25(2 Suppl 5):4–12. Epub 1998/06/03. PMID: 9609103.

10. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Molecular cancer therapeutics. 2002; 1(3):227–35. Epub 2002/12/07. PMID: 12467217.
11. Tournigand C, Andre T, Achille E, Liedo G, Flesh M, Mery-Mignard D, et al. FOLFIIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(2):229–37. Epub 2003/12/06. https://doi.org/10.1200/jco.2004.05.113 PMID: 14657227.

12. Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, et al. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun. 1997; 236(3):804–7. Epub 1997/07/30. https://doi.org/10.1006/bbrc.1997.7059 PMID: 9245737.

13. Wellmann S, Buhrer C, Moderegger E, Zelmer A, Kirschner R, Koehne P, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci. 2004; 117(Pt 9):1785–94. Epub 2004/04/13. https://doi.org/10.1242/jcs.01026 PMID: 15075239.

14. Lleonart ME. A new generation of proto-oncogenes: Cold-inducible RNA binding proteins. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer. 2010; 1805(1):43–52. http://dx.doi.org/10.1016/j.bbcan.2009.11.001.

15. Wellmann S, Truss M, Bruder E, Tornillo L, Zeimer A, Seeger K, et al. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatric Research. 2010; 67(1):35–41. Epub 2009/09/23. https://doi.org/10.1203/PDR.0b013e3181c13326 PMID: 19770690.

16. Ehlen A, Brennan DJ, Nodin B, O’Connor DP, Eberhard J, Alvarado-Kristensson M, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010; 8:78. Epub 2010/08/24. https://doi.org/10.1186/1479-5876-8-78 PMID: 20727170; PubMed Central PMCID: PMCPMC2936876.

17. Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M, et al. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmo Diet and Cancer Study. J Transl Med. 2011; 9:114. Epub 2011/07/23. https://doi.org/10.1186/1479-5876-9-114 PMID: 21777469; PubMed Central PMCID: PMCPMC3156749.

18. Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlen M, Jirstrom K, et al. Decreased expression of the RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in uterine cervical cancer. BMC Urol. 2013; 13:17. Epub 2013/04/10. https://doi.org/10.1186/1471-2490-13-17 PMID: 23565664; PubMed Central PMCID: PMCPMC3635919.

19. Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, et al. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011; 5(11–12):624–35. Epub 2011/10/01. https://doi.org/10.1002/prca.201100020 PMID: 21956899.

20. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, et al. Nuclear expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci. 2015; 128(14):2635–46. Epub 2015/04/07. https://doi.org/10.1242/jcs.128354 PMID: 25944507; PubMed Central PMCID: PMCPMC4482506.

21. Melling N, Simon R, Mirlacher M, Izbicki JR, Stahl P, Terracciano LM, et al. RBM3 expression loss is associated with right-sided localisation and poor prognosis in colorectal cancer. Histopathology. 2015; 68:191–8. Epub 2015/04/30. https://doi.org/10.1111/his.12726 PubMed PMID: 25922889.

22. Jonsson L, Hedner C, Gaber A, Korkocik D, Nodin B, Uhlen M, et al. High expression of RBM3 correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. PLoS One. 2015; 10(3):e0121300. Epub 2015/03/27. https://doi.org/10.1371/journal.pone.0121300 PMID: 25811459; PubMed Central PMCID: PMCPMC4374873.

23. Olofsson SE, Nodin B, Gaber A, Eberhard J, Uhlen M, Jirstrom K, et al. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. PLoS One. 2015; 10(3):e0121300. Epub 2015/03/27. https://doi.org/10.1371/journal.pone.0121300 PMID: 25811459; PubMed Central PMCID: PMCPMC4374873.

24. Jonsson L, Hedner C, Gaber A, Korkocik D, Nodin B, Uhlen M, et al. High expression of RBM3 correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer. PLoS One. 2015; 10(3):e0121300. Epub 2015/03/27. https://doi.org/10.1371/journal.pone.0121300 PMID: 25811459; PubMed Central PMCID: PMCPMC4374873.

25. Sorbye H, Dragomir A, Sundstrom M, Pfeiffer P, Thunberg U, Bergfors M, et al. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS One. 2015; 10(6):e0131046. Epub 2015/06/30. https://doi.org/10.1371/journal.pone.0131046 PMID: 26121270; PubMed Central PMCID: PMCPMC448806.

26. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science (New York, NY). 2015; 347(6220):1260419. https://doi.org/10.1126/science.1260419 PMID: 25613900.
27. Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp. 2012;(63). https://doi.org/10.3791/3620 PMID: 22688270; PubMed Central PMCID: PMCPMC3468196.

28. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011; 104(5):856–62. Epub 2011/02/03. https://doi.org/10.1038/bjc.2011.19 PMID: 21285991; PubMed Central PMCID: PMCPMC3046210.

29. Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. The American surgeon. 2004; 70(12):1103–6. Epub 2005/01/25. PMID: 15663054.

30. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer research. 2008; 28(3b):1797–804. Epub 2008/07/18. PMID: 18630463.

31. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. The American journal of pathology. 2001; 159(6):2249–56. Epub 2001/12/06. https://doi.org/10.1016/S0002-9440(10)63075-1 PMID: 11733374; PubMed Central PMCID: PMCPMC1850582.